相似文献
1
Chemotaxis for polymorphonuclear leucocytes induced by soluble antigen- antibody complexes.
Immunology. 1977 Dec;33(6):937-45.
2
[Induction of chemotaxis by soluble immune complexes].
Ann Immunol (Paris). 1977 Jan-Mar;128(1-2):255-7.
3
Inhibition of polymorphonuclear leucocyte locomotion by surface-bound antigen-antibody complexes.
Immunology. 1983 Jun;49(2):329-36.
4
[Studies on the influence of immune complexes on the in-vitro-migration of human blood-granulocytes (author's transl)].
Allerg Immunol (Leipz). 1977;23(4):313-21.
5
6
Chemotaxis inhibition induced in polymorphonuclear neutrophils by soluble immune complexes.
Int Arch Allergy Appl Immunol. 1979;58(4):365-74. doi: 10.1159/000232216.
7
[Suppression of thrombocyte aggregation by immune complexes. II. The effect of preformed immune complexes on thrombocyte aggregation].
Biull Eksp Biol Med. 1983 Feb;95(2):21-3.
8
9
Fc receptor-mediated desensitization of superoxide (O2-) generation response of guinea-pig macrophages and polymorphonuclear leucocytes.
Immunology. 1985 Aug;55(4):629-38.
10
Enhancement of monocyte complement component synthesis by antigen--antibody complexes.
Immunology. 1981 Sep;44(1):193-200.
引用本文的文献
1
Inhibition of PMN leukocytes chemotaxis by thalidomide.
Arch Dermatol Res. 1980;269(3):275-80. doi: 10.1007/BF00406421.
2
3
Investigations on vitamin E and lipid peroxide status in rheumatic diseases.
Clin Rheumatol. 1983 Sep;2(3):259-63. doi: 10.1007/BF02041400.
4
Pathopysiological aspects of immune complex diseases. Part II. Phagocytosis, exocytosis, and pathogenic depositions.
Klin Wochenschr. 1980 Jun 16;58(12):593-605. doi: 10.1007/BF01477835.
本文引用的文献
1
NONPRECIPITATING ANTIBODY AND THE ARTHUS VASCULITIS.
J Immunol. 1964 Jan;92:118-27.
2
[Measurement of catalase activity].
Biochem Z. 1955;327(4):255-8.
3
The requirement for the association of two adjacent rabbit gamma-G-antibody molecules in the fixation of complement by immune complexes.
J Immunol. 1968 Feb;100(2):407-13.
4
The assay of a plasma component necessary for the generation of a plasminogen activator in the presence of Hageman factor (Hageman factor co-factor).
Br J Haematol. 1971 Feb;20(2):209-16. doi: 10.1111/j.1365-2141.1971.tb07029.x.
5
Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation.
J Exp Med. 1971 Apr 1;133(4):713-39. doi: 10.1084/jem.133.4.713.
6
The fixation of complement and the activated first component (C1) of complement by complexes formed between antibody and divalent hapten.
J Exp Med. 1970 Apr 1;131(4):783-802. doi: 10.1084/jem.131.4.783.
7
Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.
Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372-5. doi: 10.1073/pnas.68.6.1372.
8
Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates.
J Exp Med. 1971 Nov 1;134(5):1131-43. doi: 10.1084/jem.134.5.1131.
9
The interaction of Hageman factor and immune complexes.
J Clin Invest. 1972 Oct;51(10):2736-45. doi: 10.1172/JCI107093.
10
Determination of soluble immune complex molar composition and antibody association constants by ammonium sulfate precipitation.
J Immunol. 1974 Feb;112(2):451-61.
Zotero 插件